Izotropic (CSE:IZO; OTC:IZOZF; FSE:1R3) is developing a dedicated breast imaging system aimed at the better detection – and potentially earlier diagnosis and treatment – of breast cancer.
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
KA Imaging launches subscription model for portable X-ray device
Closely-held KA Imaging introduced a new hardware subscription model to help U.S. and Canadian hospitals acquire Reveal 35C, the company’s portable X-ray device, during the pandemic. Reveal 35C is a portable, single...
BlueRock co-founder, Gordon Keller, receives 2020 Bloom Burton award
Gordon Keller, Ph.D., co-founder of BlueRock Therapeutics, received the 2020 Bloom Burton award, which honors an individual who has made the most significant contribution to Canada’s innovative healthcare industry. In...
Urovant Sciences vibegron fails Phase 2a IBS trial
Urovant Sciences (NASDAQ:UROV) reported disappointing topline results from its Phase 2b trial of vibegron for the treatment of abdominal pain due to irritable bowel syndrome (IBS) in women. The study failed to meet its...
FDA clears Neuronetics TouchStar protocol for major depressive disorder
The FDA cleared Neuronetics’ (NASDQ:STIM) TouchStar protocol for the treatment of major depressive disorder. TouchStar is a three-minute intermittent theta burst protocol administered using the company’s NeuroStar...
Capricor initiates dosing in Phase 2 COVID-19 trial
Capricor Therapeutics (NASDAQ:CAPR) dosed the first two patients in its Phase 2 trial evaluating CAP-1002 for the treatment of severe COVID-19. CAP-1002 is an intravenously delivered allogeneic cardiac cell therapy...
Oramed initiates Phase 3 oral insulin trials
Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) began screening patients for its two Phase 3 trials evaluating ORMD-0801 for the treatment of Type 2 diabetes. The trials will enroll a total of 1,125 Type 2 diabetes patients...
PolyPid D-PLEX100 gets FDA breakthrough therapy designation
The FDA granted PolyPid’s (NASDAQ:PYPD) D-PLEX100 breakthrough therapy designation for the prevention of surgical site infections in patients undergoing colorectal surgery. D-PLEX100 is designed to provide prolonged...
Analysts start SQZ Biotechnologies at buy
Analysts with Stifel and BTIG launched coverage of SQZ Biotechnologies (NYSE:SQZ) with “buy” ratings and price targets of $38 and $40, respectively. The stock closed at $27.62 on Nov. 23. “We believe SQZ’s Cell Squeeze...
HCW starts Curis at buy; PT $5
H.C. Wainwright initiated coverage of Curis (NASDAQ:CRIS) with a “buy” rating and price target of $5. The stock closed at $1.35 on Nov. 23. Curis is developing two novel therapeutics for three potential indications that...
iBio receives U.S. patent for endostatin peptides for the treatment of fibrosis
iBio (NYSE AMERICAN:IBIO) received a patent from the U.S. Patent and Trademark Office, covering a novel expression cassette that enhances the yield of endostatin fragments and variants using iBio’s FastPharming System...
FDA clears Orchard Therapeutics IND for OTL-200
The FDA cleared Orchard Therapeutics’ (NASDAQ:ORTX) IND for OTL-200, a stem cell-based gene therapy for the treatment of metachromatic leukodystrophy (MLD). MLD is caused by a mutation in the arylsulfatase-A gene, which...
FDA approves Eiger’s Zokinvy for progeria
The FDA approved Eiger BioPharmaceuticals’ (NASDAQ:EIGR) Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies. Progeria is an extremely rare and fatal disease caused by a...
Just a few of the companies we’ve highlighted along the way
